Showing posts with label Personalized Medicine. Show all posts
Showing posts with label Personalized Medicine. Show all posts

Thursday, January 22, 2015

Right Drug, Right Time

Today's guest post comes from Genome Editing Applications sponsor Horizon Discovery.

Right Drug, Right Time
Author: Hannah Murfet, Vice-Chair CQI Next Generation Network

“Right first time” is a concept familiar to the quality profession, but it is taking on a whole new meaning since the emergence of personalised medicine. Personalised medicine aims to eradicate an often random and reactive approach to patient care by employing techniques such as genetic testing to ensure treatment is more likely to be effective and safe in a specific patient population.

Traditional approaches to drug treatment generally take a population-wide trial and error approach. That is to say that the drugs used for treatment are known to be generally effective, but their specific effect on an individual patient is often unknown. Drugs are typically tested on large patient populations in order to test for safety and efficacy. As the patient population is seldom uniform, the efficacy is reduced as the drug works well for some and not others. Personalised medicine has the opportunity to change this by allowing us to use the right drug at the right time – a prime example of root cause analysis.

The successes of personalised medicine are staking up, and include genetic testing for breast cancer, chronic myeloid leukaemia and colorectal cancer. One very well-known example is screening for BRCA1 and BRCA2 gene mutations to predict whether a patient needs preventative breast cancer treatment. Other examples include targeted therapy based on chromosome alterations in patients with chronic myeloid leukaemia and KRAS gene mutations used as biomarkers to predict the success of specific drug treatments for colorectal cancer. Seemingly, the possibilities for personalised medicine are endless.

While the upfront costs of personalised medicine are initially higher, they will be reduced in the long term as the cost of quality is reduced by removing the expense of ineffective and repeated treatments. It’s a tremendously exciting time for the pharmaceutical and medical device fields, but I also feel those in the quality profession can take something from this. The application of the right drug, at the right time, has parallels with the work of the quality profession. We aim to use the right tool, the right approach and the right improvement at the right time. So let’s take a ‘personalised medicine’ approach to business improvement. I’m sure the results will be just as powerful for improving quality.

Genome Editing Applications will take place will take place March 18-19, 2015 in Boston.  Find out more about the program.  As a reader of this blog, you can save 20% off the standard rate when you register to join us and mention code D15223BLG.  

This post is co-posted with the CQI Blog.


Share this article with your social network, just click below to share now!


Monday, June 30, 2014

Precision vs. personalized vs. stratified medicine: Let’s pick a name

By Scott Wallask
Conference Producer, IBC Life Sciences

I’m not sure why, but my 2-year-old son, Mac, has a lot of nicknames. Most of them have been given to him by his older brothers.

At varying times in my house, Mac is called:
  • • Mackey
  • • The Key, a derivative of the prior nickname
  • • Mackey James, which is funny because James is not his middle name
  • • Little Tin Shorts, a moniker which my older sons claim came from their air conditioner (I didn’t inquire further)
Now, if you don’t live with Mac or read this blog, you might never know what his actual name is after listening to my kids talk to him.

I feel the same way about personalized medicine. Or is it precision medicine? Or how about stratified medicine? Personalized health care? Targeted drug treatment? Medicine on-demand?

Okay, I’m being facetious with the final suggestion. In the end, we’re talking about the trend away from one-size-fits-all treatments to an approach that considers a patient’s genetic make-up as a prime factor in how to combat a disease that afflicts that individual.

If we’re going to sell this concept to the masses, however, it needs to have a name we can all agree to.

I don’t care how we choose it: We can draw straws or spin a wheel. The drug development community can hold a contest. World leaders can issue a proclamation.

We once had a similar problem up here in the Boston area, where the offices of IBC Life Sciences are located. There’s a highway that rings around Boston about 10 miles from the city. It goes by various names, including Interstate 95 and the Yankee Division Highway.

But long ago, the local residents decided they were going to call it by its state-designated name, Route 128. That’s what drivers, cops, and traffic reporters all call it, and this arrangement works well because we all know what highway we’re referring to.

Personalized/targeted/precision treatments need the Route 128 approach.

Learn more about the data and technology behind precision medicine at IBC’s Personalized Medicine Technology and Analytics Forum on September 19 in Philadelphia. A featured presentation from the FDA will look at the regulatory considerations behind companion diagnostics in clinical trials.

Follow Scott on Twitter @Scott_biopharma


Share this article with your social network, just click below to share now!


Friday, May 7, 2010

Biorepositories 2010 Brochure Ready for Download

The Biorepositories event is back for its 3rd year and we want you back! The 2010 program is ready for you to download. As the industry continues to evolve with increasing interest in personalized medicine, along with novel and emerging technologies, more emphasis is being placed on the value of preserving precious biological samples. Stay current on this growing field in order to significantly impact your future drug development and revenue, and drive forward biospecimen science.

Visit the webpage to find out more about the event:
http://bit.ly/9I2THK

Download the brochure here:
http://bit.ly/9MFl6h



Share this article with your social network, just click below to share now!


Wednesday, January 27, 2010

DDP 2010: Pharma Pipeline innovation in the age of the Pharmaceutical Minibuster

Chris Anderson
Author The Long Tail: Why the Future of Business is Selling Less of More and Free: The Future of a Radical Price

Chris begins the presentation by demonstrating the end of the blockbuster. He issues this in with the N Sync No Strings Attached CD, which is the best selling CD of all time. It was the last real blockbuster in music. It hasn’t been updated in the last few years, but blockbuster albums have essentially fallen off a clip in the 2000s. The demand for music is not down, the record labels are having trouble. Music playing devices, concerts, and licensing is very high. It’s now a fragmented market. There are 10 million tracks on iTunes. We’re seeing a different music landscape, and music does not fit all, techno, pops, blues, and we all choose our distinctive taste.

Supply was confused with demand, this was one example. We accept what we’re given, until the 20th century market choices have expanded from 10 to 100 choices. Demand is shaped like a bell curve, try to find a middle ground to appeal to the most customers. The Long Tail curve actually fits it better.

Long tail graph as opposed to the long tail curve: Doesn’t have an average, it goes on forever
We find that a few things are really popular, and many things are not as popular, but still appeal to a specific crowd.

The culture we grew up in was dominated by blockbuster products. This is what the retail channels want. Example: at Walmart, if two don’t sell a week, it falls off the shelves. The internet has changed business, it has infinite shelf space. The long tail has been extremely lengthened, and consumer can really find and choose what they want. With the Blockbuster industry of music, about 40% of the market was not seen.

Long tail rules: 1) If you lower the cost of creation and distribution, you can offer more products and variety. 2) “More Variety” means products are available to satisfy more minority tastes 3) There Is lots of room at the bottom for many different individualized tastes to be filled.

What does this mean for Pharma?
-Blockbusters are now Niche Busters. One size doesn’t fit all, and while niches haven’t been economic to date, they can better fulfill the market. The Pharma market is going to have to follow suite.
-Diagnostic boom of individualized patents. Companies are finding out the uniqueness of individuals.
-Electronic Medical Records. These allow for better targeting and treatment
-Informed/empowered patients – Informed can demand more specialized care. Patients can see more information, which empowers them, and can better characterize their individual needs.

Sometimes, we have to give something for free. Even though healthcare is expensive, DNA sequencing cost is decreasing in much the same why as computer chips have over the years. Free goods are not new to Pharma. It’s the patent work that is expensive to obtain, but producing the finished pill as a good costs significantly less. The cost of obtaining biology information is decreasing, so what will Pharma do to make up for the shifted revenue?



Share this article with your social network, just click below to share now!